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Abstract
Background: Most randomized controlled trials with a time-to-event outcome are designed and analysed under
the proportional hazards assumption, with a target hazard ratio for the treatment effect in mind. However, the
hazards may be non-proportional. We address how to design a trial under such conditions, and how to analyse
the results.
Methods: We propose to extend the usual approach, a logrank test, to also include the Grambsch-Therneau test of
proportional hazards. We test the resulting composite null hypothesis using a joint test for the hazard ratio and for
time-dependent behaviour of the hazard ratio. We compute the power and sample size for the logrank test under
proportional hazards, and from that we compute the power of the joint test. For the estimation of relevant quantities
from the trial data, various models could be used; we advocate adopting a pre-specified flexible parametric survival
model that supports time-dependent behaviour of the hazard ratio.
Results: We present the mathematics for calculating the power and sample size for the joint test. We illustrate the
methodology in real data from two randomized trials, one in ovarian cancer and the other in treating cellulitis. We
show selected estimates and their uncertainty derived from the advocated flexible parametric model. We
demonstrate in a small simulation study that when a treatment effect either increases or decreases over time, the joint
test can outperform the logrank test in the presence of both patterns of non-proportional hazards.
Conclusions: Those designing and analysing trials in the era of non-proportional hazards need to acknowledge
that a more complex type of treatment effect is becoming more common. Our method for the design of the trial
retains the tools familiar in the standard methodology based on the logrank test, and extends it to incorporate a
joint test of the null hypothesis with power against non-proportional hazards. For the analysis of trial data, we
propose the use of a pre-specified flexible parametric model that can represent a time-dependent hazard ratio if
one is present.
Keywords: Time-to-event data, Randomized controlled trials, Hazard ratio, Non-proportional hazards, Logrank test,
Grambsch-Therneau test, Flexible parametric model
Background
Most randomized controlled trials (RCTs) with a time-to-
event outcome are designed and analysed under the pro-
portional hazards assumption, with a target hazard ratio
(HR) for the treatment effect in mind. However, the haz-
ards may be non-proportional (non-PH). If so, questions
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MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B
6NH, UK
arise as to how best to design the trial and analyse the
results.
We believe that there may be two reasons that non-
proportional hazards are being detected more frequently
nowadays. First, phase III trials are generally much larger
today, giving more power in any given situation to detect
non-proportional hazards. Second, with the biological
revolution there are many new therapies being evaluated,
having different modes of action. For example, mono-
clonal antibodies have been evaluated for treating many
different types of cancer. They are given for a defined
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period of time (often one or two years) and then stopped.
It is entirely plausible that the effect of the intervention
might persist during the treatment period but then dimin-
ish gradually afterwards. Such behaviour, which in fact is
what has been seen in the examples given above, would
lead to non-proportional hazards.
Typically, the sample size calculation for such a trial uti-
lizes some form of logrank test. An estimate of the HR
with a confidence interval (CI) is often obtained from a
Cox model with treatment as the only covariate. If non-
PH is present, the HR is actually time-dependent and the
estimated HR that is obtained is some type of average over
the event times [1].
An alternative design approach is to alter the test used
to analyse the data by adding a test for a possible time-
dependent treatment effect. Such a joint test may have
more power than the logrank test when certain patterns
of non-PH are present. To obtain the same power as for
the logrank test under PH, an increase in the sample size
is needed, or the target power under PH may be reduced,
or the significance level of the test may be relaxed. We
call a test of this type a ‘joint test’. We envisage a sce-
nario in which we pre-specify a more robust test that has
power in the presence of non-PH. Once we have identi-
fied a ‘signal’, we can try to better understand its nature by
further analysis of the data, as outlined in principle in the
next paragraph.
Allied to the joint test, we propose the use of a joint
model, which also incorporates a possible time-dependent
treatment effect. Presentation of results of a joint model
may include Kaplan-Meier survival curves and a pre-
specified model-based estimate of the treatment effect.
This may be the estimate of the HR (with CI) at particu-
lar time points, or indeed, because of the time-dependent
nature of the results, other potentially more informa-
tive and clinically relevant quantities, such as differences
in survival curves and in restricted mean survival times
between arms [2].
The structure of the paper is as follows. In the Methods
section, we motivate and describe the joint test of the HR
and non-PH that we propose. We show how to re-power
the logrank test under PH to achieve the power desired
for the joint test. We discuss the analysis of trial data and
make a case for estimating quantities of interest, partic-
ularly those with a time-dependent perspective, using a
flexible parametric survival model as the joint model. We
deal with the important issue of pre-specifying the anal-
ysis in the protocol and statistical analysis plan. In the
Results section, we give some numerical examples show-
ing the implications of designs incorporating the joint test
for the sample size and number of events.We then present
a small simulation study of the power of the joint test
when non-PH is present. We finish with a discussion and
conclusions.
Methods
Motivation
The basic issue that concerns us is that a clinically impor-
tant treatment effect may be more complex than implied
by a simple hazard ratio (HR) between treatment arms.
For example, survival curves that diverge then converge or
even cross may suggest the mode of action of a research
treatment. A simple HR would not do justice to interpret-
ing such data. One might say, ‘just plan the sample size
according to the logrank test as usual, then test for non-
PH after that’. But if the test of non-PH is positive, how
does one proceed - particularly in cases where the logrank
test does not exhibit conventional levels of significance
and the non-PH test does? It should be noted that the
significance level of such a sequential procedure is approx-
imately double the nominal level of the logrank test, since
two independent tests have been carried out. Doubling the
probability of a type 1 error is not likely to be acceptable
to trialists.
An obvious difficulty here is the very general nature of
possible departures from PH. This makes it nigh impos-
sible to confidently and convincingly pre-specify a time-
dependent pattern of HR behaviour with which to power
the logrank test. We believe it is preferable and practically
more appealing to power it under PH, as a rough approxi-
mation to whatmight be expected, but with an adjustment
to allow a ‘second degree of freedom’ to incorporate a
rather general test of non-PH. For the latter, we suggest
the Grambsch-Therneau test [3] based on the correlation
between scaled Schoenfeld residuals and (our preference)
the ranks of the failure times.
We assume that the Grambsch-Therneau test statistic is
independent of the Cox or logrank test of the treatment
effect and under PH has a central chi-square distribu-
tion on 1 degree of freedom (d.f.). (See further comments
on this assumption in the next paragraph.) The sum of
the logrank or Cox and Grambsch-Therneau chi-square
statistics provides a test statistic whose distribution under
the global null hypothesis of identical survival functions
across treatment arms is central chi-square on 2 d.f.
To check the above assumptions, we ran some simple
simulations which we do not report in detail. In essence,
with sets of 5,000 replicated two-arm ‘trials’ with stag-
gered patient entry, we found that, in the null case, the
Grambsch-Therneau test statistic was very close to χ2 on
1 d.f. and the joint test statistic was very close to χ2 on 2
d.f. The Spearman rank correlation between the two com-
ponent test statistics was close to zero. We conclude that
the assumptions are sound.
A joint test
A ‘joint test’ is a single statistic for simultaneous testing
of more than one aspect of the global null hypothesis that
there is no difference between survival distributions in
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treatment arms. The global null hypothesis implies that
the HR for the treatment effect equals 1 and that the HR
is independent of time (that is, PH holds). The aims of a
joint test are threefold:
1. To widen the concept of ‘treatment effect’ to include
the important possibility that the HR may depend on
time since randomization, and in some cases, the
estimated HR is ‘not significant’;
2. To have planned power to detect a treatment effect
(in terms of the HR) of pre-specified magnitude
under PH;
3. To have power in cases of non-PH in which the power
of the logrank test alone could be compromised.
Our suggested joint test is as described above. Of course,
other choices are possible, notably, based on a flexible
parametric survival model with a time-dependent treat-
ment effect [4,5]. We comment further on this issue in the
Discussion.
Power
We now consider the implications for sample size and
power of replacing the logrank test with a joint test as
just described. Suppose that there is a non-null treatment
effect (HR = 1) and PH holds. In such cases, the second
component of the joint test is null, but not the first. By
applying the joint test under PH, we ‘waste’ one d.f., reduc-
ing the power compared with the more parsimonious and
(under PH) universally most powerful logrank test. Since
the logrank test is asymptotically equivalent to a Cox test,
we can equally well substitute the likelihood ratio or Wald
chi-square statistic from Cox regression on the treatment
indicator variable for the logrank chi-square statistic.
Let α be the two-sided significance level and ω the
power of the logrank test under PH. Define
z1−α/2 = −1 (1 − α/2)
zω = −1 (ω)
zz = z1−α/2 + zω
where −1 (.) is the inverse standard normal distribution
function. When HR = 1, the logrank chi-square statistic
has a non-central χ2 distribution with 1 d.f. and non-
centrality parameter zz2. The distribution of the joint test
statistic under PH is non-central χ2 with the same non-
centrality parameter of zz2, but with 2 d.f. instead of 1 d.f.
With this setup, the power ωJT of the joint test under PH
is
ωJT = 1 − F2
[
zz2,C−12 (1 − α)
]
(1)
where Fν(λ,u) is the distribution function of a non-central
χ2 variate u with ν d.f. and non-centrality parameter λ,
and C−1ν (p) is the central chi-square deviate on ν d.f. cor-
responding to probability p. For example, C−12 (0.95) 
5.99. The required functions are widely available in
software packages. In Stata, for instance, Fν (λ,u) and
C−1ν (p) are implemented as functions nchi2(ν, λ,u)
and invchi2(ν, p), respectively.
We describe our preferred approach to powering the
joint test in the Discussion. First, we describe three possi-
ble strategies.
Strategy 1: Power the logrank test as usual
This is the simplest approach. We power the logrank test
as usual and use Equation (1) to calculate the resulting
joint test power, ωJT . For example, with significance level
α = 0.05 and power ω = (0.8, 0.9) we find ωJT =
(0.709, 0.835). Many people would probably be happy with(
ω,ωJT
) = (0.9, 0.835), whereas they might find ωJT =
0.709 too low for comfort.
Strategy 2: Power the joint test
Wemight prefer to specify a power ωJT for the joint test at
significance level α under PH. What corresponding value
of ω is needed for the logrank test?
Equation (1) can be rearranged to determine ω given
ωJT :
ω = 
{√
G2
[
C−12 (1 − α) , 1 − ωJT
]
− z1−α/2
}
(2)
where Gν(u, p) is the non-centrality parameter of a non-
central χ2 variate with ν d.f. at a value p of the distribution
function. If Fν(λ,u) = p, then Gν(u, p) = λ. In Stata,
Gν (u, p) is implemented as function npnchi2( ν,u, p).
For example, suppose we require ωJT = 0.8 at α = 0.05.
According to Equation (2) we find that G2
[
C−12 (1 − α) ,
1 − ωJT
]
= 9.63469, ωLR = 
(√
9.63469 − 1.95996
)
=
0.87369. The study would therefore need power 0.874 for
the logrank test under PH, with a corresponding increase
in sample size.
Strategy 3: Relax the significance level of the joint test
An alternative to increasing the power of the logrank test,
and hence the sample size, is to increase the significance
level of the joint test to achieve power ω for the joint test.
We wish to determine the two-sided significance level,
αJT , for the joint test to have power ω under PH.With this
setup, the power of the joint test is
ω = 1 − F2
[
zz2,C−12
(
1 − αJT
)]
where zz = z1−α/2 + zω as before. Inverting this expres-
sion, we obtain
αJT = 1 − C2
[
F−12
(
zz2, 1 − ω)]
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where, for instance, F−1ν (λ, p) is implemented in Stata as
invnchi2(ν, λ, p). For example, with α = 0.05, ω = 0.9
we find αJT = 0.0985 (that is, nearly 2α). With α = 0.05,
ω = 0.8, then αJT = 0.0952. Taking αJT  2α is likely to
be adequate in practice for 0.8 ≤ ω ≤ 0.95. In most trials,
power is set at 0.8 or 0.9.
Presentation of results
Traditionally, studies with a time-to-event outcome are
designed according to a target HR and reported with an
estimate of the resulting HR and a 95% confidence inter-
val, usually obtained from a Cox regression as already
mentioned. The HR may or may not be adjusted for
covariates such as important prognostic factors or strati-
fying variables. Often, a graph of the Kaplan-Meier esti-
mates of the survival curves is presented.
In the emerging era in which the PH assumption may
fail [6,7] (for reasons we could speculate about), the tradi-
tional strategy seems inadequate. We have argued [2] for
estimating and presenting alternative measures of a treat-
ment effect which do not rely on a time-independent HR.
Here we suggest producing two closely related reports:
graphical and quantitative.
Graphical presentation
The key understanding is that most measures of clini-
cal and statistical relevance in the non-PH context are
time-dependent. These include, obviously, the traditional
survival functions, but also the HR, the difference in
restricted mean survival time between treatments [2], and
the difference in survival functions between treatments.
We propose presenting plots of all four of these quantities
against time in a single graphic image.
Restricted mean survival time (RMST) for a mortality
outcome in a trial may loosely be described as the life
expectancy over the restricted period between random-
ization and a defined, clinically relevant time horizon,
usually called t∗. With uncensored survival times t1, . . . , tn
we would first ‘truncate’ values that exceed t∗ by setting
t′i = max (ti, t∗) Then RMST = 1n
∑n
i=1 t
′
i is the usual def-
inition of a mean applied to the truncated survival times.
With right censoring, an alternative formula is needed,
namely RMST = ∫ t∗0 S (t) dt, where S (t) is an estimate of
the survival function for the n patients [8].
An example of a graphic illustrating the four outcomes
for the GOG111 trial in ovarian cancer [9] is shown in
Figure 1. The estimates are plotted on a continuous time-
scale to avoid imposing arbitrary cut-points. We have
truncated the estimates in Figure 1 to 8 years’ follow-up
since there is almost no data beyond this point. Having
sufficient follow-up is critical to obtaining reliable clini-
cal and statistical assessment of a treatment’s effectiveness
but is rarely emphasized in trial reports.
Figure 1(c) indicates that the treatment effect on the rel-
ative hazard scale is largest near t = 0 and dwindles to
HR= 1 by about t = 4 yr. The survival curves do not cross
within the interval (0, 8) yr, so the RMST difference, which
is the integrated difference between the survival curves,
increases in a monotone fashion. By t = 8 yr it reaches
about 0.8 yr, albeit with a wide confidence interval.
Quantitative results
We propose that the primary quantitative estimates are
taken as the overall HR with its confidence interval (not-
ing that the instantaneous HR may be time-dependent)
and the difference(s) in restrictedmean survival time, with
confidence interval(s).
The report of quantitative results should include the P-
values from each of the three tests (the joint test and its
two components), the joint test being the primary com-
parison and the two components as supporting evidence.
The HR from a Cox model and results from Figure 1 at
one to three clinically relevant time-point(s) should also
be reported.
For advanced ovarian cancer, for example, reporting
estimates at 2 and 5 years after randomization might be
appropriate. The overall hazard ratio and the test results
for the GOG111 trial are shown in the first row of Table 1.
The joint test statistic is highly significant (P = 0.0004),
more so in fact than either of its components.
Estimates of key quantities at 2 and 5 years of follow-up
are given in Table 2. There is a fairly substantial treatment
effect. For example, the RMST difference is ≥ 10% of the
reference follow-up time t∗ at both 2 and 5 yr.
A second example
PATCH1 is a randomized, double-blind trial comparing a
12-month course of low-dose penicillin with a placebo in
the prevention of recurrent cellulitis of the leg, a common
baterial infection of the skin and underlying tissue [10].
The trial is rather small, with 129 events (patients expe-
riencing one or more recurrences) among 274 patients
followed up for a maximum of 3 years.
The results for PATCH1 are shown graphically in
Figure 2 and in tabular form in Table 1 (we have omitted
the equivalent of Table 2 since the results are indicated in
Table 1 and Figure 2).
The results here are particularly intriguing. Neither of
the individual treatment-effect tests are formally signif-
icant at the 5% level, although both are very close to
significant (see Table 1). In contrast, the joint test has
a P-value of 0.02. The conclusions from the trial analy-
sis could hinge on which approach to testing was taken.
Figure 2(c) shows that, as with GOG111, the treatment-
effect HR appears substantial near t = 0 and diminishes
rapidly over the course of follow-up, being near 1 after 1
year. Note the generally large uncertainty in the estimates.
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Figure 1 Time-dependent outcomemeasures exemplified by the GOG111 trial in advanced ovarian cancer. (a) Kaplan-Meier curves (solid
lines) and estimated survival functions (dashed lines) from a flexible parametric model; (b) difference in survival functions; (c) instantaneous hazard
ratio; (d) difference in restricted mean survival time. Shaded areas are pointwise 95% confidence intervals. Estimates in panels (b), (c) and (d) are
derived from a flexible parametric model.
Estimation
Model for a time-dependent treatment effect
In the preceding section, we have recommended a
particular presentation of results without indicating how
the results were obtained. Obviously, the Kaplan-Meier
curves in Figure 1(a) and the hazard ratio estimate and
tests in Table 1 are standard and familiar. This cannot be
said of the other graphs and corresponding quantities in
Table 2.
There are many ways in which the curves in Figure 1
could have been estimated. None can be said to be
‘standard’. Figure 1 was actually produced using a time-
dependent, hazards-scaled flexible parametric survival
model (FPM) [4,5]. This is the model class we propose and
focus on.
Let x denote the (binary) treatment indicator variable,
coded 0 for the control arm and 1 for the research arm.
In the FPM, the baseline log cumulative hazard function,
lnH0 (t) = lnH (ln t; x = 0), is modelled parametrically
as a restricted cubic spline function of ln t, say lnH0 (t) =
s0 (ln t). The FPM we fitted can be written as
lnH (t; x) = lnH0 (t) + θ (t) x = s0 (ln t) + [θ0 + θ1 ln t] x
(3)
The function θ (t) = θ0 + θ1 ln (t) describes the time-
dependent behaviour of the ratio of log cumulative hazard
functions between trial arms as a linear function of log
time. This choice is similar to, but differs slightly from,
Cox’s suggestion [11] for modelling a time-dependent
hazard ratio. In the latter, the log hazard function is mod-
elled as ln h (t; x) = ln h0 (t) + θ (t) x = ln h0 (t) +[
θ0 + θ1 f (t)
]
x, where f (t) is some simple parametric
function of time such as ln t or
√
t.
When θ (t) is constant, that is, when θ1 = 0, the cumu-
lative hazards and hence also the hazards in the FPM are
proportional between treatment groups. Equation (3) is
then a PH model with HR equal to exp (θ0).
Table 1 Overall hazard ratio and test statistics for the GOG111 and PATCH trials
Trial Hazard ratio Joint test Cox test of HR= 1 G-T test of PH
Est. 95% CI Chi-sq. P Chi-sq. P Chi-sq. P
GOG111 0.73 (0.59, 0.90) 15.90 0.0004 8.38 0.0038 7.52 0.0061
PATCH1 0.71 (0.50, 1.00) 7.58 0.023 3.78 0.052 3.80 0.051
Est. = estimate, Chi-sq.= chi-square.
Royston and Parmar Trials 2014, 15:314 Page 6 of 10
http://www.trialsjournal.com/content/15/1/314
Table 2 Time-dependent quantitative results for the
GOG111 trial
Quantity t = 2 yr t = 5 yr
Est. 95% CI Est. 95% CI
HR(t) 0.71 (0.57, 0.89) 0.99 (0.71, 1.39)
S0 (t) 0.52 (0.46, 0.58) 0.18 (0.13, 0.23)
S1 (t) 0.68 (0.62, 0.73) 0.27 (0.22, 0.33)
S1 (t) − S0 (t) 0.16 (0.07, 0.24) 0.09 (0.02, 0.16)
RMST0 (yr) 1.53 (1.45, 1.61) 2.44 (2.22, 2.67)
RMST1 (yr) 1.73 (1.66, 1.79) 3.04 (2.81, 3.26)
RMST1− RMST0 0.20 (0.09, 0.30) 0.59 (0.27, 0.91)
Note that the estimated hazard ratio, HR(t), is instantaneous. See text for further
details.
Predefining the statistical analysis
These days, randomized controlled trials are heavily reg-
ulated in various ways. One requirement is for a detailed
statistical analysis plan to be drawn up before the trial
data are finalized and analysed. The plan should lay out
how the data will be analysed. The aim is to avoid any
temptation on the part of the investigators to interpret
the data over-optimistically by a data-driven selection of
techniques and their results. In our context, we need to
pre-specify the significance tests(s) that will be applied to
gauge the evidence for a non-null treatment effect, and
the model(s) that will be fitted to the data, from which key
estimates will be derived.
The joint test is straightforward to specify since it
requires the logrank or Cox chi-square value and the
Grambsch-Therneau chi-square statistic using, for exam-
ple, the rank transformation of the failure times. (Other
time transformations are sometimes used, but no evidence
that we are aware of favours any particular one.) The pri-
mary test of the treatment effect is then the sum of the two
chi-squares, which is tested on 2 d.f. at the appropriate sig-
nificance level. The overall HR estimate and its confidence
interval are taken from the Cox regression.
Regarding the choice of FPM, we remarked that ‘a sen-
sible default strategy . . . is to assign 3 d.f. to the baseline
distribution and 1 d.f. to a time-dependent treatment
effect to account for possible non-PH’ [2]. Further experi-
ence since that publication has confirmed that this model
specification is flexible enough to fit the vast majority of
trials we have encountered. In our approach, 3 d.f. means
that the baseline s0 (ln t) is a restricted cubic spline func-
tion with a boundary knot at each of the extreme failure
times and interior knots at the 33rd and 67th centiles
of the failure times. The baseline function is required in
the estimation of the survival and other curves shown in
Figures 1 and 2.
We have occasionally encountered trials in which the
time-dependent component, θ1 ln (t), of the treatment
Figure 2 Time-dependent outcomemeasures exemplified by the PATCH1 trial: (a) Kaplan- Meier curves (solid lines) and estimated
survival functions (dashed lines) from a flexible parametric model; (b) difference in survival functions; (c) instantaneous hazard ratio; (d)
difference in restricted mean survival time. Shaded areas are pointwise 95 intervals. Estimates in panels (b), (c) and (d) are derived from a
flexible parametric model. Follow-up has been truncated at 3 years.
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effect is more complex than a logarithmic function of
time. Such additional complexity could be investigated in
secondary analyses. However, we judge that the simplicity
and particularly the parsimony of model (3) are essential
to a robust, pre-specified primary analysis. Similarly, 3 d.f.
for the baseline spline may occasionally seem insufficient
according to, say, an information criterion. Nevertheless,
the improvement in fit to survival probabilities when fur-
ther knots are included is typically small and of little
practical importance. See also Royston and Lambert [5]
pp. 74-79.
Results
Simulation study
Weperformed a small simulation study of the power of the
joint test under non-PH. (The power under PH is known.)
We powered a hypothetical trial design under the logrank
test with a sufficient sample size and number of events for
the joint test to have power 0.8 under PH, at a two-sided
significance level of 0.05. The corresponding power of the
logrank test under PH was 0.874. The target HR was taken
to be 0.75. We assumed staggered entry of patients into
the ‘trial’ at a uniform rate for 8 years, with a subsequent
follow-up period of 4 years. Thus, the minimum andmax-
imum possible follow-up times for any patient were 4 and
12 years, respectively. The required numbers of patients
and events were 700 and 467, respectively.
Times to event were simulated under piecewise expo-
nential models according to two patterns of non-
proportional hazards, HR1 (t) and HR2 (t), representing
increasing or decreasing treatment effects, respectively.
The relevant design parameters are shown in Table 3. For
example, S0 (t) = 0.767 at t = 1 yr means that the con-
trol arm survival probability is 0.767 at t = 1. The HR for
the increasing treatment effect (HR1) is 1.00 in the interval
t ∈ (0, 1), and so the survival probability in the research
arm would also be 0.767 at t = 1. The pattern of the sur-
vival curves for PH and for the two non-PH cases is shown
in Figure 3.
The simulation was performed with 5,000 replicates.
The results are shown in Table 4. Under both patterns
of non-PH, the joint test outperforms the logrank test,
Table 3 Design parameters for the simulation study of
power
Time, t S0 (t) HR1 (t) HR2 (t) Time, t S0 (t) HR1 (t) HR2 (t)
1 0.767 1.00 0.65 7 0.302 0.60 1.0
2 0.628 0.85 0.70 8 0.268 0.60 1.0
3 0.529 0.70 0.75 9 0.238 0.60 1.1
4 0.453 0.65 0.80 10 0.213 0.60 1.1
5 0.392 0.60 0.90 11 0.191 0.60 1.2
6 0.343 0.60 0.90 12 0.172 0.60 1.2
markedly so when the treatment effect increases with
time. Under PH, the power of the joint test is of course
lower.
Numerical examples of sample size
To exemplify sample size and number of events under the
joint test, we use the same design parameters as for the
simulation study (see Table 3). We take the power for the
joint test to be 0.709 or 0.835 (corresponding to power 0.8
or 0.9 for the logrank test - strategy 1) or 0.8 or 0.9 (typical
power values chosen by practitioners - strategy 2). We set
the target HR under PH to be 0.7, 0.75 or 0.8, values com-
monly encountered in real trials. The results are shown in
Table 5.
In general, about 20 percent more events are required
by the joint test than the logrank test. For example, for
target HR = 0.75, the joint test with power 0.9 requires
logrank power 0.945 and 20.4 percent more patients and
events than the logrank test with power 0.9 (919 versus
763 patients, 613 versus 509 events).
Discussion
Our paper has two components: trial design with asso-
ciated significance testing, and estimation of results. We
discuss these briefly in turn.
There is no particular reason that we are aware of for
expecting proportional hazards of the treatment effect. It
is a convenient assumption that facilitates sample size cal-
culation in time-to-event data. Our basic design idea is
to improve the power to detect a more general, that is,
potentially more complex, treatment effect than PH. The
motivation is the increasingly frequent occurrence of non-
PH in trials, with a concern that the power of the logrank
test may be low in some of these cases. The outcome could
be a trial declared or regarded as ‘negative’, when in fact
a clinically relevant difference in survival curves between
treatments was present.
There are costs to generalizing the concept of a treat-
ment effect. Patterns of non-PH are potentially very var-
ied, and it is hard, if not impossible, to design a trial with a
convincing prior assumption about the likely pattern. Our
proposed solution is to power the trial under PH accord-
ing to a two-part (‘joint’) test. By combining the usual
logrank or Cox test with the Grambsch-Therneau test of
non-PH, we incur a loss of power under PH, but we may
gain power under non-PH.
We discussed three possible strategies for trial design:
(1) power according to the logrank test, with a hit in power
of the joint test; (2) power according to the joint test, with
an increase in sample size required via the higher power
used in the logrank test; or (3) the same strategy as (2), but
relaxing the significance level of the joint test to achieve
the same power as the logrank test.
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Figure 3 Survival curves in the control and research arms for three hazard ratio patterns. (a) Proportional hazards; (b) increasing treatment
effect; (c) decreasing treatment effect.
We have a slight preference for strategy 2. A frequent
choice, for example, in past Medical Research Council
(MRC) cancer trials has been to power the logrank test
at 90 percent with significance level 5 percent and a tar-
get HR of 0.75. As we have seen, such a design guarantees
power of 83.5 percent for the joint test under PH, which
many would consider adequate. Others may have different
preferences. We indicate how to do the relatively straight-
forward power calculations in the present paper. Sophisti-
catedmethodology and software (for example, [12,13]) are
available for implementing complex trial designs under
the logrank test. These can of course also be used with the
joint test under PH.
The Grambsch-Therneau test is based on scaled
Schoenfeld residuals derived from a Cox PH model.
Schoenfeld residuals are unsuitable for estimation of the
Table 4 Power of tests under different scenarios:
simulation results
Test Treatment effect
Constant (PH)a Increasing (HR1)b Decreasing (HR2)c
Logrank 0.874 0.719 (0.006) 0.820 (0.005)
Joint 0.800 0.854 (0.005) 0.855 (0.005)
aUnder proportional hazards with HR = 0.75.
bSimulation mean HR = 0.790.
cSimulation mean HR = 0.767.
Values under PH are exact theoretical figures. Other values are the proportions
of 5,000 simulation replicates in which the joint null hypothesis was rejected.
Values in parentheses are Monte Carlo standard errors.
quantities of substantive interest in a survival analysis of
trial data. For that reason, for estimation, we suggest using
a flexible parametric model with a time-dependent treat-
ment effect. This class of models can be pre-specified in
sufficient detail in a protocol and statistical analysis plan.
It provides smooth estimates of survival probabilities, haz-
ard ratio functions, restricted mean survival times, and
Table 5 Example of sample size calculation for the joint
test under PH
Power of test under PH Target HR Sample size
Logrank Joint n events
0.8 0.709 0.70 378 248
0.75 570 380
0.80 931 632
0.9 0.835 0.70 506 332
0.75 763 509
0.80 1246 845
0.874 0.8 0.70 464 304
0.75 700 467
0.80 1142 775
0.945 0.9 0.70 610 399
0.75 919 613
0.80 1500 1018
The power for the logrank test is given in the first column. The corresponding
power of the joint test is shown in the second column.
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so on. While there is a potential risk of bias due to the
FPM failing to fit the data adequately, our experience so
far is that noticeable lack of fit to the survival functions is
uncommon. Of course, the Cox model can also fit badly.
The time-dependent treatment effect function incor-
porated in the FPM is log-linear in the follow-up time
and therefore of limited flexibility. The fit can be checked
by inspecting a plot of smoothed Schoenfeld residuals
against the failure times, which gives a ‘non-parametric’
impression of the pattern of the log hazard ratio over
time. If necessary, in secondary analysis the FPM can
be elaborated with further spline parameters to improve
the fit.
A sensible alternative to the joint test we describe is a
joint test of the two parameters θ0 and θ1 in the FPM.
This test, also on 2 d.f., is of the treatment effect and its
interaction with (log) time. The global null hypothesis is
θ0 = θ1 = 0 (see Equation (3)). In an informal compari-
son using a database of 25 heterogeneous RCTs, we found
good agreement and no consistent differences in the P-
values of the two joint tests (data not shown). At this point,
we have no empirical evidence to support recommending
one test over the other. However, one theoretical con-
sideration favouring the Cox/Grambsch-Therneau joint
test is that the Grambsch-Therneau test is more general
than the time-dependent function θ0 + θ1 ln t. It is con-
ceivable, therefore, that the Cox/Grambsch-Therneau test
may tend to have higher power in general than the FPM-
based joint test. On the other hand, some researchers may
favour congruence between the global test for a treat-
ment effect being based on the FPM and the same FPM
being used in the description and interpretation of the
trial results.
A key feature of the joint test is that it is sensitive to
simple and also to more ‘complex’ treatment effects. In
the latter case, assuming the result is not a type 1 error,
the test is indicating there is a genuine difference between
the survival curves. Even if the overall treatment effect,
considered over the entire follow-up time of the trial, is
small, the difference between the armsmay still be of clini-
cal and/or scientific interest and importance. For example,
the difference in the survival curves between the treat-
ment arms may suggest possible mechanisms of action of
the treatments.
We are not suggesting that the joint test be adopted
routinely. Primarily, we suggest that the trialist choose
the preferred test according to the perceived modes of
action of the treatments being compared. If the modes
are obviously different, for example surgery versus a more
conservative approach such as watchful waiting or a non-
surgical therapy, the hazard functions will probably differ
markedly in shape and non-PH seems more likely. The
joint test may then be a good choice. If rather similar
treatments are involved, such as various chemotherapy
regimens, non-PH may seem less likely and the logrank
test may be best. There may be indications of the extent
and nature of non-PH from earlier trials or, in cancer for
example, from other cancer types in which the treatment
has been evaluated. Another consideration is judging how
close to PH the ensuing survival curves are likely to be.
If a treatment effect is expected to emerge relatively soon
after randomization, non-PH is likely to be mild and
the logrank test will be the more powerful. If the effect
emerges much later in follow-up, the joint test is likely to
be more powerful.
Conclusion
The design and analysis of trials in the era of non-
proportional hazards needs to accommodate a wider con-
sideration of the nature of treatment effects. We have
suggested one way forward which retains the tools famil-
iar in the standard approach to trial design and sample
size under proportional hazards, but which utilizes a
joint test of the null hypothesis with power against non-
proportional hazards. The trialist can choose whether
to pay the price of the generalization by increasing the
sample size or relaxing the significance level used in the
joint test. We recommend the former. For analysis of the
trial data, our approach pre-specifies a flexible parametric
model that can represent a time-dependent hazard ratio if
one is present.
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